The <scp><i>BRAF</i>^V</scp>^600E mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?

Abstract

The presence of the activating BRAF(V) (600E) mutation in a significant percentage of papillary thyroid microcarcinoma indicates that further analyses are required to verify its usefulness as a predictor of clinical outcome in PTC. In this study, there was no correlation between BRAF-positive primary focus of papillary microcarcinoma and more aggressive or recurrent disease.